• Assessing the RLT landscape, providing insights into current target successes and guiding future discovery to accelerate development and patient impact
• Opportunities and challenges for RLT R&D, incl. target identification and prioritization (Understanding the rarity of “ideal” targets like PSMA and somatostatin receptors and the implications for success)
• Defining the strategic fit of RLTs, highlighting how they complement existing oncology modalities and enable precision, combination, and patient-tailored therapies
• Future Landscape: a glimpse to the future development of target selection

New Company for 2026